title: A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan.
abstract: BACKGROUND
  The combination of paclitaxel (225 mg/m(2), 3 h infusion) and carboplatin [area under the curve (AUC) 6 mg/ml x min] is used widely for non-small cell lung cancer in the USA and is one of the standard regimens in the Southwest Oncology Group. In Japan, however, the upper limit of the approved dose for single-use paclitaxel is 210 mg/m(2) and the optimum dose of this agent in combination with carboplatin has not yet been established. This study was designated to determine whether the paclitaxel dose of 225 mg/m(2 ) plus carboplatin (AUC = 6) is tolerable for Japanese patients with untreated advanced non-small cell lung cancer.
  
  
  METHODS
  Ten patients were enrolled between October 1999 and June 2000 and all of these patients were evaluable for toxicity. Chemotherapy consisted of carboplatin (AUC = 6 mg/ml x min) and 225 mg/m(2 )of paclitaxel on day 1 every 3 weeks.
  
  
  RESULTS
  Neutropenia was the major toxicity and grade 4 neutropenia was observed in seven of the 10 patients (70%), but febrile neutropenia was not observed. Grade 4 anemia as a dose-limiting toxicity was observed in two patients. This was due to gastric ulcer bleeding in both patients. Only one patient experienced grade 3 peripheral neuropathy. No grade 3 or more myalgia or arthralgia was reported. Overall, 44 courses of chemotherapy were administered in 10 patients. Partial responses were observed in six of the 10 patients (60%). Median survival time was 7.7 months.
  
  
  CONCLUSIONS
  Paclitaxel at 225 mg/m(2) in a 3 h infusion and carboplatin AUC = 6 appears to be tolerable in Japanese patients with untreated advanced non-small cell lung cancer.
authors.affiliation: Department of Internal Medicine, National Kinki-Central Hospital for Chest Diseases, Sakai, Osaka, Japan.
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Ogawara
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kawahara
authors.forename: Shigeto
authors.initials: S
authors.lastname: Hosoe
authors.forename: Shinji
authors.initials: S
authors.lastname: Atagi
authors.forename: Tomoya
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Okishio
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Naka
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Sunami
authors.forename: Shigeki
authors.initials: S
authors.lastname: Mitsuoka
authors.forename: Koji
authors.initials: K
authors.lastname: Inoue
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Haryu
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Yoneda
authors.forename: Hideki
authors.initials: H
authors.lastname: Origasa
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D016190:Carboplatin; D017239:Paclitaxel